ArsenalBio to Present Four Abstracts on CAR T Cells for Solid Tumors at ASGCT Annual Meeting

Arsenal Biosciences, Inc., a clinical-stage company specializing in programmable cell therapy to develop advanced CAR T-cell therapies for solid tumors, has announced the presentation of four abstracts at the American Society of Gene + Cell Therapy (ASGCT) annual meeting in Baltimore, from May 7-11, 2024. These presentations focus on innovative solutions ArsenalBio is developing to address the unmet needs in solid tumor cancers, including ovarian and kidney cancers.

Nick Haining, Co-Founder and Chief Scientific Officer of ArsenalBio, highlighted the company's progress in advancing CAR T-cell therapy. He emphasized the company's rigorous approach and robust data, which led to the clinic entry of their second T cell medicine within five years, aimed at providing safe and effective treatments for solid tumor cancers.

The abstracts will be presented as posters during the ASGCT meeting:

1. Abstract 811: Development of AB-2100, a PSMA-inducible anti-CA9 CAR T cell therapy intended for the treatment of ccRCC
- Date and Time: May 8, 2024, at 12:00 p.m.
- Presenter: Mark Landon, M.S.
- Details: AB-2100 is an autologous integrated circuit T (ICT) cell product designed to treat relapsed/refractory clear cell renal cell carcinoma (ccRCC). It incorporates a DNA cassette that uses a logic gate requiring the presence of two antigens and includes mechanisms to armor the T cells against immunosuppression. This approach was validated in xenograft models, showing efficacy in targeting tumors expressing CA9 and both PSMA and CA9.

2. Abstract 782: Development of a microscopy-based IF/ISH assay for detection of ICT cells in patients treated with AB-1015
- Date and Time: May 8, 2024, at 12:00 p.m.
- Presenter: Nickolas Attanasio
- Details: AB-1015 is being developed for ovarian cancer treatment and features an "AND" logic gate to limit off-tumor toxicity. A custom multiplex immunofluorescence (mIF) assay was developed to detect ICT cells in human tissue using the RNAScope platform. This assay was validated in xenograft models and used to detect ICTs in a tumor biopsy sample from an AB-1015 patient.

3. Abstract 839: Single-cell, pooled CRISPR screening reveals T cell intrinsic regulators of exhaustion in context of chronic antigen stimulation
- Date and Time: May 8, 2024, at 12:00 p.m.
- Presenter: Glenn Wozniak, Ph.D.
- Details: This research utilized CRISPR/Cas9-based screening combined with deep sequencing to identify genetic perturbations that prevent T cell exhaustion. By developing genetically engineered CAR T cells and subjecting them to chronic antigen stimulation, the study identified potential genetic targets to enhance T cell function, providing insights for future CAR T cell therapy development.

4. Abstract 814: Development of logic-gated “Payload” module in CAR T cells aimed at increasing local concentration of a secreted pro-inflammatory module in an antigen-dependent manner
- Date and Time: May 8, 2024, at 12:00 p.m.
- Presenter: Gavin Shavey, M.S.
- Details: This study investigated whether a logic-gated secretion of a pro-inflammatory module (Payload) could enhance the anti-tumor response by supporting the endogenous immune system. By engineering and testing over 30 cytokine variants, the study demonstrated that these Payloads significantly augmented anti-tumor activity in vitro and in vivo without increasing transformation risk.

Arsenal Biosciences, Inc., based in South San Francisco, focuses on developing next-generation autologous T cell therapies to combat cancer. Utilizing a comprehensive R&D engine enabled by CRISPR-mediated DNA insertion, ArsenalBio aims to build a large DNA library of therapeutic enhancing integrated circuits. Their approach seeks to improve efficacy, patient safety, cost efficiency, and market access through a computational and nonviral clinical manufacturing methodology.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!